{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T16:10:51Z","timestamp":1772208651553,"version":"3.50.1"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,27]]},"DOI":"10.7759\/cureus.104392","type":"journal-article","created":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T15:20:19Z","timestamp":1772205619000},"source":"Crossref","is-referenced-by-count":0,"title":["Metastatic Medullary Thyroid Carcinoma in Multiple Endocrine Neoplasia Type 2B (MEN 2B) With RET M918T Mutation: Challenges in Long-Term Management and Targeted Therapy"],"prefix":"10.7759","author":[{"given":"Zehra","family":"Rahman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barrie","family":"Clark","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kabeer","family":"Ali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hamza","family":"Choudhry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Layton","family":"Weimer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin","family":"Parza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriela","family":"Bastidas Mora","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2014.0335","article-title":"Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma","volume":"25","author":"Wells SA Jr","year":"2015","unstructured":"Wells SA Jr, Asa SL, Dralle H, et al.. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid. 2015, 25:567-610. 10.1089\/thy.2014.0335","journal-title":"Thyroid"},{"key":"ref2","article-title":"Medullary thyroid cancer","author":"Santillan VR","year":"2024","unstructured":"Santillan VR. Medullary thyroid cancer. StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL); 2024."},{"key":"ref3","doi-asserted-by":"crossref","DOI":"10.1210\/jcem.86.12.8070","article-title":"Guidelines for diagnosis and therapy of MEN type 1 and type 2","volume":"86","author":"Brandi ML","year":"2001","unstructured":"Brandi ML, Gagel RF, Angeli A, et al.. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab. 2001, 86:5658-71.","journal-title":"J Clin Endocrinol Metab"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2010-1921","article-title":"High prevalence of RAS mutations in RET-negative sporadic medullary thyroid carcinomas","volume":"96","author":"Moura MM","year":"2011","unstructured":"Moura MM, Cavaco BM, Pinto AE, Leite V. High prevalence of RAS mutations in RET-negative sporadic medullary thyroid carcinomas. J Clin Endocrinol Metab. 2011, 96:E863-8. 10.1210\/jc.2010-1921","journal-title":"J Clin Endocrinol Metab"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2008.0403","article-title":"Medullary thyroid cancer: management guidelines of the American Thyroid Association","volume":"19","author":"Kloos RT","year":"2009","unstructured":"Kloos RT, Eng C, Evans DB, et al.. Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid. 2009, 19:565-612. 10.1089\/thy.2008.0403","journal-title":"Thyroid"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/2.7.851","article-title":"Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC","volume":"2","author":"Donis-Keller H","year":"1993","unstructured":"Donis-Keller H, Dou S, Chi D, et al.. Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Hum Mol Genet. 1993, 2:851-6. 10.1093\/hmg\/2.7.851","journal-title":"Hum Mol Genet"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-18-0056","article-title":"Clinical significance of RET and RAS mutations in sporadic medullary thyroid carcinoma: a meta-analysis","volume":"25","author":"Vuong HG","year":"2018","unstructured":"Vuong HG, Odate T, Ngo HT, et al.. Clinical significance of RET and RAS mutations in sporadic medullary thyroid carcinoma: a meta-analysis. Endocr Relat Cancer. 2018, 25:633-41. 10.1530\/ERC-18-0056","journal-title":"Endocr Relat Cancer"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13184670","article-title":"Long-term outcomes and causes of death among medullary thyroid carcinoma patients with distant metastases","volume":"13","author":"Park H","year":"2021","unstructured":"Park H, Yang H, Heo J, Kim TH, Kim SW, Chung JH. Long-term outcomes and causes of death among medullary thyroid carcinoma patients with distant metastases. Cancers (Basel). 2021, 13:4670. 10.3390\/cancers13184670","journal-title":"Cancers (Basel)"},{"key":"ref9","article-title":"Vandetanib for the treatment of medullary thyroid cancer","volume":"19","author":"Chau NG","year":"2013","unstructured":"Chau NG, Haddad RI. Vandetanib for the treatment of medullary thyroid cancer. Clin Cancer Res. 2013, 19:524-9.","journal-title":"Clin Cancer Res"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2309719","article-title":"Phase 3 trial of selpercatinib in advanced RET-mutant medullary thyroid cancer","volume":"389","author":"Hadoux J","year":"2023","unstructured":"Hadoux J, Elisei R, Brose MS, et al.. Phase 3 trial of selpercatinib in advanced RET-mutant medullary thyroid cancer. N Engl J Med. 2023, 389:1851-61. 10.1056\/NEJMoa2309719","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2005651","article-title":"Efficacy of selpercatinib in RET-altered thyroid cancers","volume":"383","author":"Wirth LJ","year":"2020","unstructured":"Wirth LJ, Sherman E, Robinson B, et al.. Efficacy of selpercatinib in RET-altered thyroid cancers. N Engl J Med. 2020, 383:825-35. 10.1056\/NEJMoa2005651","journal-title":"N Engl J Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-023-00522-4","article-title":"Circulating cell-free DNA (cfDNA) in patients with medullary thyroid carcinoma is characterized by specific fragmentation and methylation changes with diagnostic value","volume":"11","author":"Citarella A","year":"2023","unstructured":"Citarella A, Besharat ZM, Trocchianesi S, et al.. Circulating cell-free DNA (cfDNA) in patients with medullary thyroid carcinoma is characterized by specific fragmentation and methylation changes with diagnostic value. Biomark Res. 2023, 11:82. 10.1186\/s40364-023-00522-4","journal-title":"Biomark Res"},{"key":"ref13","article-title":"","year":"2010","unstructured":"AJCC Cancer Staging Manual, 7th Edition. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A (ed). Springer, New York, NY; 2010. https:\/\/www.facs.org\/media\/j30havyf\/ajcc_7thed_cancer_staging_manual.pdf."},{"key":"ref14","article-title":"Multiple endocrine neoplasia type 2","author":"Eng C","year":"2023","unstructured":"Eng C. Multiple endocrine neoplasia type 2. GeneReviews\u00ae [Internet]. Pagon RA, Adam MP, Ardinger HH, et al. (ed): University of Washington, Seattle, Seattle (WA); 2023."},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2017-01039","article-title":"Prognostic significance of circulating RET M918T mutated tumor DNA in patients with advanced medullary thyroid carcinoma","volume":"102","author":"Cote GJ","year":"2017","unstructured":"Cote GJ, Evers C, Hu MI, et al.. Prognostic significance of circulating RET M918T mutated tumor DNA in patients with advanced medullary thyroid carcinoma. J Clin Endocrinol Metab. 2017, 102:3591-9. 10.1210\/jc.2017-01039","journal-title":"J Clin Endocrinol Metab"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2006.02559.x","article-title":"Very early prophylactic thyroid surgery for infants with a mutation of the RET proto-oncogene at codon 634: evaluation of the implementation of international guidelines for MEN type 2 in a single centre","volume":"65","author":"Piolat C","year":"2006","unstructured":"Piolat C, Dyon JF, Sturm N, et al.. Very early prophylactic thyroid surgery for infants with a mutation of the RET proto-oncogene at codon 634: evaluation of the implementation of international guidelines for MEN type 2 in a single centre. Clin Endocrinol (Oxf). 2006, 65:118-24. 10.1111\/j.1365-2265.2006.02559.x","journal-title":"Clin Endocrinol (Oxf)"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1002\/jso.26790","article-title":"Clinical features and oncological outcomes of primary female urethral cancer","volume":"125","author":"Lee W","year":"2022","unstructured":"Lee W, Yu J, Lee JL, Kim YS, Hong B. Clinical features and oncological outcomes of primary female urethral cancer. J Surg Oncol. 2022, 125:907-15. 10.1002\/jso.26790","journal-title":"J Surg Oncol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1177\/10507256251367352","article-title":"Patient-reported tolerability of selpercatinib compared to cabozantinib\/vandetanib: a secondary analysis of the LIBRETTO-531 Randomized-controlled trial in RET-mutant medullary thyroid cancer","volume":"35","author":"Elisei R","year":"2025","unstructured":"Elisei R, Wirth LJ, Capdevila J, et al.. Patient-reported tolerability of selpercatinib compared to cabozantinib\/vandetanib: a secondary analysis of the LIBRETTO-531 Randomized-controlled trial in RET-mutant medullary thyroid cancer. Thyroid. 2025, 35:1162-72. 10.1177\/10507256251367352","journal-title":"Thyroid"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2015.0373","article-title":"Five years of cancer drug approvals: innovation, efficacy, and costs","volume":"1","author":"Mailankody S","year":"2015","unstructured":"Mailankody S, Prasad V. Five years of cancer drug approvals: innovation, efficacy, and costs. JAMA Oncol. 2015, 1:539-40. 10.1001\/jamaoncol.2015.0373","journal-title":"JAMA Oncol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1210\/endrev\/bnad013","article-title":"Medullary thyroid cancer: updates and challenges","volume":"44","author":"Gild ML","year":"2023","unstructured":"Gild ML, Clifton-Bligh RJ, Wirth LJ, Robinson BG. Medullary thyroid cancer: updates and challenges. Endocr Rev. 2023, 44:934-46. 10.1210\/endrev\/bnad013","journal-title":"Endocr Rev"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.84.7.5861","article-title":"Changes in free insulin-like growth factor-1 and leptin concentrations during acute metabolic decompensation in insulin withdrawn patients with type 1 diabetes","volume":"84","author":"Attia N","year":"1999","unstructured":"Attia N, Caprio S, Jones TW, et al.. Changes in free insulin-like growth factor-1 and leptin concentrations during acute metabolic decompensation in insulin withdrawn patients with type 1 diabetes. J Clin Endocrinol Metab. 1999, 84:2324-8. 10.1210\/jcem.84.7.5861","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/445027-metastatic-medullary-thyroid-carcinoma-in-multiple-endocrine-neoplasia-type-2b-men-2b-with-ret-m918t-mutation-challenges-in-long-term-management-and-targeted-therapy","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T15:20:20Z","timestamp":1772205620000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/445027-metastatic-medullary-thyroid-carcinoma-in-multiple-endocrine-neoplasia-type-2b-men-2b-with-ret-m918t-mutation-challenges-in-long-term-management-and-targeted-therapy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,27]]},"references-count":21,"URL":"https:\/\/doi.org\/10.7759\/cureus.104392","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2,27]]}}}